INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2005

Chondroitin sulfate treatment for 2 years significantly reduced joint space loss compared to placebo in patients with knee osteoarthritis.

In a randomized, double-blind, placebo-controlled trial, 300 patients with knee osteoarthritis were assigned to receive 800 mg chondroitin sulfate (CS) or placebo once daily for 2 years. Patients receiving placebo experienced a mean joint space loss of 0.14 +/- 0.61 mm after 2 years (P = 0.001 compared with baseline), whereas patients receiving CS showed no change (0.00 +/- 0.53 mm; P not significant compared with baseline). The difference in joint space loss between the two groups was significant for mean joint space width (0.14 +/- 0.57 mm; P = 0.04) and minimum joint space width (0.12 +/- 0.52 mm; P = 0.05). There was no significant symptomatic effect on pain or function, and CS was well tolerated.

Study type
Randomized, double-blind, placebo-controlled trial
Who was studied
300 patients with knee osteoarthritis
What was measured
Joint space loss over 2 years, pain, and function

THE PAPER

Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial.

Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, Uebelhart D. Arthritis Rheum, 2005.

PubMed 15751094 ↗DOI 10.1002/art.20867 ↗

Bones & musclesOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.